1. EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know

3. Program Overview

4. PAH Diagnostic Tools

5. PAH: Importance of Early Diagnosis to Improve Patient Outcomes

6. Diagnostic Algorithm for PH

7. Echocardiographic Probability of PH in Symptomatic Patients With a Suspicion of PH

8. Other Echocardiographic PH Signs

9. PAH Diagnostic Tools (cont)

10. Hemodynamic Definitions of PH as Assessed by RHC

11. Hemodynamic Parameters Measured or Derived From RHC

12. PAH Treatment: General Strategy

13. PAH Treatment: General Measures

14. PAH Treatment: Supportive Therapy

15. PAH Treatment: Specific Drug Therapy

16. Prognostic Evaluation and Risk Assessment

17. Initial Combination Therapy for High-Risk Patients With PAH

18. Initial Combination Therapy for Low/Intermediate-Risk Patients With PAH

19. Initial Use of Ambrisentan Plus Tadalafil in PAH: The AMBITION Trial

20. AMBITION Trial: Primary Endpoint* Results

21. ERS/ESC Evidence-Based Treatment Algorithm for Patients With PAH

22. PAH Therapies Target Diverse Vasomotor Pathways

23. Combination Therapy in PAH: Rationale and Potential Clinical Benefits

24. Role of Monotherapy for the Treatment of PAH

25. Pathobiology of PAH

26. Initial Combination Therapy for the Treatment of PAH

27. AMBITION: Efficacy Results

28. AMBITION Primary Endpoint* Results by Subgroup

29. Initial vs Sequential Combination Therapy: How to Choose?

30. Follow-Up Strategy for Patients With PAH

31. Conclusions

32. Conclusions (cont)

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)